What's new in canine otitis externaFebruary 24, 2026Advances in longer-acting medications, improved formulations, and enhanced diagnostics are transforming the management of canine ear infections. These innovations benefit dogs, their owners, and veterinarians alike.
Education Center - SponsoredIntegrating Therapeutic Nutrition for Chronic Allergiesby • Hill's Pet NutritionIntended for veterinary audiences
Exercise therapy for managing OAFebruary 23, 2026Veterinarians have a host of therapeutic options for their patients suffering from OA, including oral medications, targeted joint injections, supplements, weight management, as well as modalities, such as shockwave therapy or photobiomodulation, and acupuncture. Each therapy consideration has its unique advantages and precautions. However, when reflecting on the many beneficial effects of exercise in patients with joint pain, it is easy to see why our profession should promote it as a primary intervention.
Pet food additives–concerning, or no big deal?February 19, 2026Veterinarians will need to be conversant with the pros and cons of fresh, freeze-dried, frozen, and ultra-processed formulations. With artificial additives being a big part ultra-processed foods’ bad reputation, let’s begin with those.
Brain Teaser: Can you solve this puzzle?February 17, 2026Test your veterinary knowledge with our monthly challenge, featuring a three-year-old male intact Beauceron presenting for six hours of lethargy, non-productive vomiting, and restlessness.
A close look at monoclonal antibodies for managing canine OA painJanuary 15, 2026As veterinary care continues to shift toward preventive medicine and lifelong wellness, there is growing momentum around improving earlier detection and more consistent pain management. Among the emerging therapeutic options is a new class of biologics: monoclonal antibodies (mAbs).
Brain Teaser: Can you solve this puzzle?January 7, 2026Presentation: A five-month-old intact female Pomeranian with right forelimb lameness after jumping off a step.
USDA approves drug for canine allergic and atopic dermatitisJanuary 6, 2026Befrena (tirnovetmab), an anti–IL-31 monoclonal antibody injection for the treatment of canine allergic and atopic dermatitis, is intended for use in dogs of any age and is recommended at dosing intervals of six to eight weeks following treatment.
Providing therapeutic options to manage canine atopic dermatitisDecember 30, 2025Veterinarians need a solid understanding of the available therapeutic options to make appropriate recommendations for patients. Additionally, understanding our clients’ perspectives is key to devising successful management plans that fit their needs and desired outcomes.
